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Abstract 
Introduction 
Medication non-adherence is a serious barrier to treatment of schizophrenia. Understanding the 
impact of non-adherence on costs is essential to the assessment of the cost-effectiveness of 
interventions in which adherence to treatment is a concern. 
Objectives 
We undertook a comprehensive review of the available literature on the impact on costs of non-
adherence to antipsychotics in the treatment of schizophrenia. 
Methods 
We performed a search on multiple databases (MEDLINE, Embase, PsycINFO and Health 
Management Information Consortium) for any study reporting the impact of adherence to 
antipsychotics on costs in patients with schizophrenia up to February 2018. We included trials of 
behavioural interventions but excluded comparisons of different pharmacological therapies. Studies 
were included if at least one third of the study population had schizophrenia and costs were 
reported. 
Results 
Thirty-four publications on 28 studies met the inclusion criteria. Twenty studies reported analyses of 
administrative databases, primarily Medicaid. Findings on health care costs were mixed but 
suggested that lower pharmacy costs in non-adherent patients may outweigh increased 
hospitalisation costs where drug costs are relatively high. A few studies published analysis of 
prospective cohort data, or trials of behavioural interventions intended to influence adherence, 
mainly in a European setting. Findings were again mixed but indicate that increasing adherence does 
not reduce overall costs. 
Conclusions 
Inference from analysis of administrative data is limited by the risk of selection bias. Inference from 
trials is limited by small sample sizes. The literature does not consistently support an assumption 
that non-adherence increases health care cost. 
 
Key points 
• An assumption prevails that non-adherence increases treatment costs for schizophrenia due 
to increased risk of hospitalisation 
• The available evidence suggests that decreases in other costs, primarily pharmacy costs in the 
US, may offset increased hospital costs arising from non-adherence 
• There is insufficient evidence to conclude which direction health care costs change with 
decreasing adherence; an assumption of no change is more defensible than an assumption 
that costs rise  
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1. Introduction 
Schizophrenia is a life-long condition characterised by frequent relapses during which patients 
exhibit psychotic symptoms [1]. These psychotic episodes are often severe enough to necessitate 
stabilisation and treatment in psychiatric hospitals, and schizophrenia patients are likely to be 
hospitalised many times during their lifetime. Treatment with antipsychotics can reduce the 
frequency of relapse, offering the potential to reduce the high costs of managing schizophrenia 
patients [2]. However, antipsychotics are associated with severe side-effects including weight gain, 
development of diabetes and movement disorders [3]. The side-effects of treatment and the extent 
to which patients may lack insight into their disease contribute to high treatment switching and 
discontinuation rates [4]. Reported compliance rates range from 20% to 72% for schizophrenia 
patients [5]. Many patients are partially compliant and may take ‘treatment holidays’ of varying 
duration. Hence non-adherence may manifest itself as a gap in medication or partial fill of 
prescriptions. 
Measuring compliance is challenging. Patient and physician reports are subjective and both parties 
may have a tendency to exaggerate compliance [6,7]. Pharmacy records are objective but are also 
likely to overestimate compliance since not all prescribed medication will be consumed. Individuals 
who fill at least 80% of prescriptions are generally considered to be adherent and those who fill 
between 50% and 80% are generally considered partial adherent [8]. Measures of compliance based 
on records of prescription fills are most commonly quantified as the Medication Possession Ratio 
(MPR) - the number of days of medication supply in the index period divided by the number of days 
in the index period (often 365) [9]. Variations include the Proportion of Days covered which is 
equivalent to the MPR with values capped at 1. In a comparison of eight measures of adherence, 
lower adherence on all measures was associated with a higher risk of hospitalisation amongst 
schizophrenia patients, and MPR and PDC were the best predictors of hospitalisations, but the 
differences between measures were small [10]. 
A number of studies have reviewed the literature around the causes and consequences of, and 
interventions to reduce non-adherence [11-19]. These reviews and other evidence [20,21] point to a 
consensus that non-adherence leads to greater risks of poor functional outcomes including relapse 
and associated hospitalisation, suicide and violent behaviour. Whilst the side-effects of medication 
can themselves be a cause of hospitalisation there is strong evidence to indicate increased 
hospitalisation associated with non-adherence [12,17]. Early studies of both intermittent treatment 
and tapered discontinuation demonstrated both were associated with increased hospitalisation 
rates [22,23]. 
Hospital stays are expensive and likely to be increased in poorly adherent patients. However, non-
adherence may reduce the cost of drug treatment which can form a sizable proportion of total 
treatment costs in the US. Hence the impact on overall costs is less obvious. An early review of the 
literature concluded that ‘a definitive relationship exists between compliance and the economic 
costs of schizophrenia’ [19]. However, that review included studies published prior to 2003, most of 
which were primarily intended to compare drug treatments. More recent reviews have concluded 
there is a link between non-adherence and hospitalisation, but have failed to find a link between 
adherence and overall costs [12,13]. This paper reviews the literature relating to the costs associated 
with non-adherence and discontinuation of treatment and reappraises the evidence regarding the 
impact of non-adherence on costs. 
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2. Methods 
A structured search of MEDLINE, Embase, PsycINFO and HMIC Health Management Consortium was 
undertaken on 27th February 2018 for articles reporting on the cost of adherence or discontinuation 
of treatment for schizophrenia. The search algorithm (provided in the appendix) included the 
following in the title, abstract or keywords: cost$, schizophrenia, recidivis$, non-complian$, 
noncomplian$, complian$, continu$, discontinu$, non-adheren$, nonadheren$, adheren$, cessat$, 
cease$, stop$, recidivis$. Citations of all identified relevant articles were also searched and 
references checked. We applied the following inclusion criteria: 
1. Publications in English 
2. Over one third of the study population diagnosed with schizophrenia or schizoaffective 
disorder 
3. The study reported costs 
4. Trials of interventions to modify adherence which included a comparison of costs 
Studies reporting only the impact on hospitalisation rates were excluded. Modelling studies and 
reviews were excluded. Conference abstracts were included if they reported the impact of 
adherence on costs. We included trials of behavioural interventions designed to modify compliance 
where such trials reported a difference in adherence which was significant at the 5% level, but 
excluded trials comparing different pharmacological therapies. Observational studies analysing the 
impact of adherence on costs were included regardless of the original purpose of recruitment (e.g. 
trials which failed to demonstrate an impact on adherence). We extracted data on the impact of 
adherence on the costs of hospitalisations, pharmacy costs and total costs where these were 
available. Where data are reported both unadjusted and adjusted for patient characteristics we 
report the adjusted data. 
The quality of the evidence from included studies was assessed using the following criteria selected 
to highlight aspects of design or reporting relevant to the research question: 
• reporting of price year 
• assessment of adherence using more than one source 
• assessment of compliance in the period prior to costs rather than concurrently 
• identification and separate analysis of patients over filling prescriptions 
• identification and separate analysis of patients switching or augmenting medication 
• use of study design or regression analysis to control for confounding on observed patient 
characteristics 
• use of study design or regression analysis to control for confounding on unobserved patient 
characteristics. 
3. For each criterion, studies were assessed as meeting the 
criterion, not meeting the criterion or unclear where insufficient 
reporting prevented assessment.Results 
The electronic database search identified 1932 publications after removing duplicates. After initial 
screening, 152 original publications were retained (Figure 1). On examination, 27 publications met 
the inclusion criteria. A further 4 studies were identified through searches of references and 
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citations and supplementary information on included studies was obtained from 3 additional 
publications. In total, 34 publications on 28 studies met the criteria and were included in the review. 
The majority of the relevant literature originated from the US and presented analysis of 
administrative databases in which prescription fill data were used to identify patients with a 
medication gap (Table 1). There was a small body of literature reporting economic evaluations 
alongside clinical trials. Three of the four trials were of interventions to boost adherence; only one 
trial randomised patients to discontinuation of therapy. Patients were generally recruited in an 
outpatient setting and adherence was assessed by patient questionnaire or physician interview. 
Finally, we included four analyses of the impact of adherence on costs based on survey data or 
prospective cohort studies, of which some were recruited for a randomised trial. 
3.1 Analysis of administrative databases 
Twenty studies reported on analyses of administrative databases [24-43] of which 17 were US based 
[24-40] and 13 analysed Medicaid data [24-36]. A conference abstract provided additional cost data 
for one of the studies [44]. Sample sizes varied from 354 to 87,015. Most studies excluded patients 
with gaps in eligibility or enrolment status of 1-2 months or more, institutionalized patients, and 
patients on depot medications for whom treatment is generally administered by a clinician. 
Adherence was most often quantified as the MPR. The scope of these studies was generally limited 
to health care costs and some studies considered only hospital and pharmacy costs. Two studies 
contrasted the impact of adherence on mental and physical health care costs [26,40] and one study 
included criminal justice costs [27]. The complexity of these studies ranged from simple comparisons 
of costs across patient groups categorised by compliance to a sophisticated analysis of longer term 
costs which controlled for endogeneity using instrumental variables. Follow-up periods over which 
costs were assessed were commonly a year with some studies assessing compliance in a prior index 
period (of typically one year’s duration). 
3.1.1 Unadjusted comparisons across adherence groups 
Nine studies examined the impact of adherence on costs without explicit consideration of 
medication switching, augmentation or excess filling [24-27,37,38,40-42]. All except one evaluated 
adherence and costs over the same period; one study evaluated the impact of adherence in the first 
year on costs in the second [40]. Most report comparisons of cost data without controlling for 
differences in patient characteristics although one publication matched patients according to length 
of follow-up and type of insurance [40]. Four publications undertook multivariate regression 
modelling of costs [24-26,40]. The study by Svarstad and colleagues was notable as the only study 
which assessed adherence from more than one data source [24]. In two studies non-adherence was 
qualified as a treatment gap [38,41], and one study characterised adherence according to the 
number of complete years with outpatient elective psychiatric care and/or PDC>0.5 [42]. One study 
examined adherence to antipsychotics and to cardio-metabolic medication in 87,015 Medicaid 
patients with schizophrenia and cardio-metabolic comorbidities [25]. Robertson et al. examined the 
impact of adherence in the three months following discharge from psychiatric hospital on healthcare 
and criminal justice costs [26].  
Six of the seven studies reporting hospital costs found a reduction in hospital costs associated with 
adherence [24,26,37,38,40,42]. All five studies which reported drug costs found increasing costs 
associated with adherence [26,27,37,38,42]. With regard to total costs the picture was mixed; three 
studies found higher costs for adherent patients [25,41,42] and three studies found lower costs 
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[26,27,38]. A further study which did not report total costs found a reduction in pharmacy costs in 
non-adherent patients which more than offset the increase in hospitalisation costs [37]. Robertson 
and colleagues found lower overall costs in non-adherent patients despite the inclusion of criminal 
justice costs which were higher amongst non-adherent patients [27]. One study undertook separate 
cost comparisons for patients prescribed typical antipsychotics, atypical antipsychotics or both [25]. 
Costs rose with increasing non-adherence across all three subgroups of patients. However, the 
differences were less amongst patients prescribed atypical antipsychotics where drug costs were 
higher.  
3.1.2 Separate analysis of ‘switchers’ and ‘augmenters’ 
Three studies specifically addressed treatment switching and indicated that amongst adherent 
patients, those switching or augmenting drug therapy have higher costs [28-30]. All analysed 
Medicaid data. An early study partitioned 2476 patients into those receiving no therapy (17%), and 
those who delayed treatment (27%), switched or augmented therapy (32%), or maintained initial 
treatment without delay (25%) [28]. A poster presentation from the same group compared patients 
‘persistent’ with a single therapy to non-persistent patients and patients augmenting their therapy 
[29]. Both studies applied regression analysis to control for differences in observed patient 
characteristics across groups. The third study applied latent class analysis to 36,195 Medicaid 
patients and identified three underlying classes of patients: adherent patients (14%); partially 
adherent patients (21%) and non-adherent patients (65%) [30]. Treatment switching was rare 
amongst both adherent patients and non-adherent patients but very common in the partially 
adherent group. 
Two of the three studies reported inpatient and drug costs [28,30]. Inpatient costs were lowest 
amongst adherent patients. Patients switching therapy had the highest drug costs, non-adherent 
patients had the lowest drug costs. All three studies reported total costs and found the highest costs 
amongst patients switching or augmenting treatment. Two of the three studies found lower total 
costs amongst non-adherent patients compared to adherent patients [29,30]. The third study found 
lower costs in patients with a treatment gap compared to non-adherent patients but higher costs in 
patients receiving no drug treatment for their schizophrenia [28]. 
3.1.3 Separate analysis of ‘excess fillers’ 
Three studies distinguished patients who filled prescriptions in excess of their prescribed treatment 
(excess fillers) from patients compliant with medication and reported increased hospitalisation risk 
and higher costs for excess fillers [31,32,43]. Adherence was measured as MPR and excess fillers 
defined as those with MPR greater than 1.1 to 1.25 across the three studies. All three studies used 
regression analysis to adjust for differences in patient characteristics across adherence groups and 
one included a propensity score in the adjustment [43]. Two of the three studies reported inpatient 
costs, drug costs and total costs from analysis of Medicaid data [31-32]. Both found higher inpatient 
costs amongst excess fillers and non-adherent patients compared to adherent patients and 
increasing drug costs with increasing proportion of prescriptions filled. However, only one of the two 
studies found lower total costs in non-adherent patients compared with adherent patients [31]. The 
third study reported higher costs in both non-adherent patients and excess fillers compared with 
adherent patients, but it was unclear whether the costs reported included drugs [43].  
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3.1.4 Application of quasi-experimental design or statistical analysis to control for 
unobserved confounding 
Three analyses used more sophisticated designs to estimate the impact of non-adherence 
[33,34,39]. Two of the studies compared adherence and cost data within patients over time to 
eliminate the impact of time invariant unobserved patient characteristics [33,39]. Both exploited an 
exogenous shock in the form of an increase in medication copayments falling on patients. Farley 
compared Mississippi Medicaid data before and after a rise in co-payments with comparator states 
with minimal co-payments finding the change induced a 5% reduction in compliance and 4% 
reduction in mental health costs [33]. The change in costs may have been influenced by the 
simultaneous 5% cut in physician reimbursement introduced with the copayment change. Zeber and 
colleagues compared trends in hospitalisation rates for 20 months before and after an increase in 
copayments in 40,654 patients subject to the copayment and 39,983 patients with a military waiver 
[39]. The copayment rise was associated with a decrease in psychotropic pharmacy fills and a 
modest but significant increase in hospitalisations. A subsequent conference presentation estimated 
the cost of the changes in resource use associated with the copayment change and reported cost 
increases in excess of the revenue from the copayment change [44].  
The final study applied two instrumental variables, the copayment rate and the availability of postal 
medication fills, in a two stage least squares (TSLS) analysis of annual costs for 32,374 Medicaid and 
commercially insured patients with schizophrenia or bipolar disorder [34]. The TSLS analysis 
generated results sharply in contrast to the simple linear regression (OLS). Both OLS and TSLS 
analysis indicated higher annual hospital costs associated with non-adherence and with early 
discontinuation of therapy.  OLS regression indicated an annual total cost (of which hospital costs 
are one element) decrease of $3,071 associated with non-adherence and a similar decrease of 
$3,705 associated with early discontinuation. In contrast, TSLS analysis indicated a rise in annual 
total cost of $19,497 associated with non-adherence and a rise of $23,927 associated with early 
discontinuation. 
3.1.5 Other studies 
Marcus & Olfson estimated the hospital costs attributable to non-adherence in schizophrenia using 
US population level data [35]. Regression analysis was used to determine the relative risk of 
hospitalisation associated with non-adherence and the impact on length of stay. Annual 
hospitalisation costs associated with schizophrenia were estimated at $860million (2005 USD), of 
which $106million could be attributed to non-adherence. Markowitz and colleagues examined 
adherence and costs for 2,541 Medicaid patients from six months prior to 12 months after 
schizophrenia-related hospitalisation [36]. Adherence was defined as MPR ≥ 0.8. Adherence declined 
from 63% to 46% prior to admission. Adherence rose to 78% in the two months after discharge and 
then settled back to circa 60%. Despite higher adherence, more inpatient admissions occurred in the 
first two months following discharge compared to the next two months (13.9% vs 8.3%; p < 0.001) 
and schizophrenia related total costs were higher ($2,708 vs $2,102; 2010 USD; p < 0.001).     
3.2 Cohort studies 
Six reports from four cohort studies have published data on adherence and costs (table 1) [45-50]. 
Three of the studies collected data prospectively [46-48] and one analysed survey data [45]. 
Adherence was assessed by clinician interview in two of the studies [47,48] and possibly also a third 
[46], although the method of assessment of adherence was not clearly reported. All studies used 
8 
 
regression analysis to estimate the impact of adherence. Two of the cohorts were recruited to RCTs 
[46,48]. QUATRO randomised patients in four European cities to adherence therapy or usual care 
[48]. No significant impact of the intervention on adherence was observed. The MECCA study trialled 
a computer mediated intervention (DIALOG) to improve patient-clinician communication and found 
a significant effect of the intervention on quality of life [46]. 
Two of the four studies reported the impact of adherence on inpatient costs and both reported a 
rise with non-adherence [45,47] although neither reported a significant difference (at the 5% level). 
The only study which analysed the impact of adherence on drug costs reported increased costs 
associated with non-adherence at baseline [46]. Two of the four studies found increasing total costs 
associated with non-adherence [45,47] and two studies reported total costs decreasing with non-
adherence [46,48]; none found the difference in total cost to be statistically significant at the 5% 
level. 
3.3 Trials 
Economic evaluations have been published for four RCTs in which the intervention led to a 
significant change in compliance [51-58] (table 2). Two of the trials tested behavioural therapies to 
increase adherence [52,56], one trial tested financial incentives [58] and one trial tested guided 
discontinuation of antipsychotic therapy [54]. All the trials were of modest size. The earliest and 
smallest trial reported higher costs in the control group at baseline and follow-up, and found no 
statistically significant differences in cost between treatment and control at the 5% level [51]. More 
recent trials of adherence therapy and financial incentives reported improved adherence in the 
intervention arm along with a non-significant (at 5%) increase in costs [55,57]. In the final trial 128 
Dutch first episode psychosis patients (45% with schizophrenia) were randomized to guided 
discontinuation or maintenance therapy [54]. Despite a higher relapse rate, total costs over 18 
months following discontinuation were lower in the intervention group, driven primarily by lower 
hospitalisation costs, but differences were not significant at the 5% level [53]. The maintenance 
group had higher costs at baseline and a higher proportion of patients with schizophrenia. 
3.4 Summary of the evidence 
• Adherence lowers hospitalisation costs but increases pharmacy costs 
• Evidence of the impact of adherence on total costs from analysis of both administrative 
databases and cohort studies is mixed 
• ‘Switchers’, ‘augmenters’ and ‘overfillers’ cost more than adherent patients, but studies 
excluding them do not necessarily find adherence is associated with lower total cost 
• Evidence of the impact of adherence on total costs from trials and observational studies 
which controlled for unobserved confounding is also mixed.  
3.5 Assessment of methodological quality 
Figure 2 presents the results of the assessment of the methodological quality of the analyses of non-
randomised studies. There is no indication that the methodological quality of studies has improved 
over time. Indeed, three of the four studies which met none of the assessment criteria were 
published after 2012 [37,38,42]. Most studies undertook regression modelling to adjust for baseline 
differences in patients across comparison groups but many failed to report the relevant year for cost 
data. Separate comparison of medication switchers and excess fillers is more commonly undertaken 
in the literature prior to 2013. Some studies addressed the temporal impact of non-adherence on 
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costs or risk of hospitalisation either by design or during analysis, but very few studies addressed the 
risk of confounding on unobserved patient characteristics. 
4. Discussion 
The evidence from the available literature on the costs of non-adherence confirms the link between 
non-adherence and both hospitalisation rates and hospital costs. The fall in pharmacy costs 
associated with non-adherence might also have been anticipated, but our review confirms this. The 
combined impact of these two opposing trends on overall costs is harder to discern. The majority of 
analyses of US databases have shown a fall in overall costs associated with non-adherence. This may 
reflect high drug costs in the US combined with relatively short length of stay for hospitalised 
patients limiting the cost impact of increased hospitalisation. Database analyses from South Korea, 
Thailand and the Netherlands indicate rising costs with non-adherence. This may reflect lower drug 
costs relative to inpatient costs in these countries. In contrast to the database analyses the majority 
of cohort studies and RCTs reported on European populations. Here, again the evidence on the 
impact of adherence on total costs is mixed, although the majority of more recent studies indicate a 
rise in total costs with increasing adherence. 
The limited number of studies which isolated patients switching or augmenting therapy indicate a 
tendency for such patients to accrue higher costs than those adherent to a single therapy. Hence 
inclusion of such patients might be expected to increase the costs for adherent patients. Despite 
this, those studies which did compare patients adherent to a single therapy with non-adherent 
patients generally found adherence to be associated with higher overall costs. Patients filling excess 
prescriptions also incur higher drug costs than patients filling the correct number of prescriptions. 
The motivation to fill prescriptions for antipsychotics in excess of prescribed treatments are unclear, 
but may be associated with other lifestyle factors which increase treatment costs [31]. Again, 
inclusion of these patients with adherent patients is likely to increase the costs for adherent 
patients. Two of the three studies which isolated excess fillers found lower total costs amongst 
adherent patients compared to non-adherent patients.  
For both augmentation of treatment and excess prescription fills a direct link with increasing drug 
costs might be expected. It also seems likely that patients who switch or augment treatment have 
more severe disease than patients who persist with a single therapy, although they may be not be 
more severe than non-adherent patients. Assuming severity is directly related to costs, incomplete 
adjustment for case-mix is likely to bias analysis. The scope to adjust for case-mix using observed 
patient characteristics may be very limited in administrative databases. Results from the single study 
which controlled for endogeneity using instrumental variables suggest that higher costs amongst 
adherent patients arise from unobserved differences with non-adherent patients and that after 
controlling for these differences costs are sharply lower amongst adherent patients [34]. This finding 
should be treated with caution as simulation studies have demonstrated the sensitivity of TSLS 
procedures to the strength of the instrumental variables [59]. 
The experimental and quasi-experimental studies offer the opportunity to examine the impact of 
adherence on costs with control of unobserved confounding through experimental design. The 
evidence from the four trials reviewed would suggest that increasing adherence does not reduce 
costs and may be associated with a modest rise in costs. However, the size of the studies limits 
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inference from them. The two quasi-experimental studies which exploited a co-payment increase for 
prescription drugs analysed large samples, but generated conflicting results [33,39]. This small body 
of literature would suggest costs do not fall with increased adherence after controlling for patient 
severity. 
Our findings suggest that interventions to improve adherence may not deliver cost savings overall. 
However, improvements in adherence may well deliver benefits to patients and their families. Such 
a goal ought to be the primary motivation of interventions to improve adherence and may well 
justify the financial investment.     
4.1 Methodological quality of literature 
A single study appraisal tool would be limited in its ability to highlight strengths and weaknesses 
across the diverse types of study in our review. Instead, we chose to examine aspects of study 
implementation and reporting of particular relevance to our research question, and applicable to all 
the included studies. Figure 2 highlights a number of limitations, some of which are inherent in the 
research designs. Inevitably, studies of administrative data rely on prescription records to quantify 
adherence. An assumption that prescribed medication is consumed is unavoidable, but the failure of 
most of these studies to isolate ‘excess fillers’ is an avoidable weakness. Such patients present an 
increased risk of hospitalisation, as well as increasing pharmacy costs, possibly as a result of 
unobserved patient characteristics. Identification of the direction of causation and control for 
selection bias is a challenge for any observational study. Few of the analyses based on administrative 
data attempted to isolate the temporal pattern of non-adherence and resource use, and only three 
attempted to control for unobserved confounding across comparison groups [33-35,39]. The 
dominance of US settings limits the generalizability of the findings from the literature reporting 
administrative database analyses. The reliance of observational studies on patient reports for 
assessment of compliance is an avoidable limitation. Exaggeration of compliance may have blunted 
comparisons across compliance groups; the SOHO study reported high compliance rates (71%) and 
very modest differences in costs across comparison groups [47,49]. 
4.2 Comparisons with previous reviews 
Four previous reviews have examined the cost of non-adherence and all concluded that non-
adherence increases hospital costs, but only one review concluded non-adherence increases total 
costs. An early review included 12 studies which were predominantly a mixture of observational 
studies and trials primarily designed to compare different antipsychotics [19]. The authors concluded 
that lower compliance was associated with higher treatment costs. Dilla and colleagues reviewed 
eight studies reporting noncompliance and cost data of which four were analyses of Medicaid data 
and two were reports of mirror-image studies [12]. They modestly concluded that interventions to 
improve adherence could improve patient quality of life without substantially increasing treatment 
costs. A review of US studies of hospitalisation costs (7 studies including a mixture of administrative 
database analyses and modelling studies) found an association between adherence and lower 
hospital costs [17]. Higashi and coworkers reviewed 12 studies examining the relationship between 
adherence and hospitalisation [13]. The authors reported a consistent link between non-adherence 
and hospitalisation risk but did not summarise the evidence on costs. 
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4.3 Strengths and limitations 
This review sought to capture all of the available evidence on the impact of non-adherence on costs, 
and to provide a balanced perspective on the disparate and often conflicting evidence base. We 
excluded studies which reported exclusively on the impact of non-adherence on hospitalisation rates 
where there is ample evidence of a link. Our research question and subsequent search strategy 
concerned the cost of non-adherence. We included all studies of antipsychotics in psychosis patients 
in populations with at least some schizophrenia patients and trials of interventions intended to 
change adherence. Although we searched a limited number of databases, we undertook extensive 
efforts to search articles cited in and citing relevant retrieved studies to ensure that all relevant 
publications were captured. We did not apply a formal assessment of quality since the diverse 
nature of the studies would have been poorly represented by a single measure. Instead we highlight 
indicators of quality which are relevant to most studies and to the research question. 
The preponderance of studies from US settings limits the generalizability of our findings. Whilst the 
cost of a psychiatric bed day in the US is likely to be higher than in most other settings, typical length 
of stay is short. Hence overall hospitalisation costs may well be higher in European settings. 
Pharmacy costs also appear to be higher in US settings. These differences will act synergistically to 
raise the relative costs of non-adherence compared to adherence in Europe compared with the US. 
Few studies in our review included costs falling outside health sectors. Whilst costs falling on 
criminal justice appear to be modest, there are likely to be considerable additional costs associated 
with relapse which fall on other public sector budgets. The impact of non-adherence on these costs 
is difficult to predict; evidence from the two large observational, European studies which collected 
cost data outside health is conflicting [47,48]. Evidence of the impact of non-adherence on 
productivity costs is lacking, but it seems likely that non-adherence would increase them. Only a 
handful of studies examined the temporal effect of adherence on costs and those that did typically 
examined costs in the following 12-18 months. The longer term impact of adherence on costs is 
poorly studied. A further limitation of the review is the exclusion of patients on depot medication by 
most studies. The impact of non-adherence in this group may be moderated by greater residual 
levels of antipsychotics. Finally, it is important to emphasise that this review considered only costs. 
Increased relapse rates and hospitalisation arising from non-adherence may have a detrimental 
effect on the quality of life of patients and their relatives. 
5. Conclusions 
An assumption that overall health care costs rise with non-adherence is not supported by the 
literature. Indeed, there is some evidence from more recent analyses of US administrative data and 
a small trial literature to suggest costs fall with non-adherence. Comparisons of costs across 
adherent and non-adherent patient subgroups in administrative databases are subject to the risk of 
selection bias. Trials of behavioural interventions intended to manipulate compliance provide an 
opportunity to circumvent selection bias, but published studies are too small to provide definitive 
conclusions on the impact of adherence on costs. In the meantime, an assumption that changes in 
adherence have no overall impact on health care costs, ceteris paribus, may be the most defensible.  
12 
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Tables 
Reference Database/
study 
Observ-
ation 
Years 
No. of 
pati-
ents 
Follow-
up 
period  
Costs 
included 
Adherence categories 
considered 
Annualised difference in costs 
between adherence categories# 
(statistical significance) 
Price Year 
and 
currency 
Patients 
with 
schizo-
phreniaa hospital Drugs total 
Database analysis – comparison of costs between adherent and non-adherent patients 
Svarstad 
2001 [24] 
Medicaid ‘89 –‘90 619 1 year 
Psychiatric 
hosp. costs 
Some/no quarters without 
therapy 
$2,356**b nr nr nr USD 67%c 
Becker 
2007 [25] 
Medicaid ‘99 –‘00 10,330 2 years 
Mental 
health care, 
some crimed 
MPR <0.25 vs >=0.75 nr nr $2,483e (ns) 
nr USD 100% MPR 0.25-0.499 vs >=0.75 nr nr $1,911e (ns) 
MPR 0.5-0.749 vs >=0.75 nr nr $522e (ns) 
Offord 
2013a [37] 
Medicare ‘05 –‘10 354 1 year 
All health 
care 
MPR>=0.7; MPR<0.7 
$4,031 
(ns) 
-$3,514*** nr nr USD 100% 
Offord 
2013b [38] 
US private ‘06 –‘09 1,462 1 year? 
All health 
care 
Time to 30d drug gap of >90d; 
<90d 
$1,639* -$3,766*** -$2,236 (ns) nr USD 100% 
Hansen 
2012 [26] 
Medicaid ‘04 –‘08 87,015 1 year 
All health 
care 
PDC>=0.8; PDC<0.8 $4,603f -$5,539f -$5,701f 2008 USD 100% 
Robertson 
2014 [27] 
Medicaid ‘02 –‘08 1,367 
Unclear
mean 65 
months 
Mental 
health care, 
crime 
including 
arrest and 
incarceration 
MPR>=0.8 for 31-60d vs 61-
90d in 90d 
-$2,100 -$1,848 -$6,348 
nr USD 84% 
MPR>=0.8 for 1-30d vs 61-90d 
in 90d 
-$792 -$3,084 -$6,984 
MPR>=0.8 for 0d vs 61-90d in 
90d 
-$6,576 -$4,332 -$15,552 
Roberto 
2017 [40] 
Medicare ’11-‘12 13,681 2nd year Hospital costs 
PDC>=0.90 vs PDC<0.70 -$888***g nr nr 
2012h 
USD 
100% PDC 0.80-0.89 vs PDC<0.70 -$723**g nr nr 
PDC 0.70-0.79 vs PDC<0.70 -$544g nr nr 
Joe 2016 
[41] 
Korean 
Insurance 
2011 7,848 
Mean 
320d 
Psychiatric 
and medical 
care costs 
MPR>=0.8 vs MPR<0.8 Nr nr 843,000 
2011 
KRW 
100% 
Treat. gap>56d vs gap<=56d Nr nr 948,000 
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van der 
Lee 2016 
[42] 
Dutch 
insurance 
’09-‘11 7,392 3 years 
All health 
care 
3 years cont. carei vs 2 years €12,328 -€699 €9,341 2009-
2011j 
Euro 
100% 3 years cont. carei vs 1 year €10,782 -€997 €5,700 
3 years cont. carei vs 0 years €5,808 -€1,143 -€1,067 
Database analysis  - Switchers analysed separately 
McCombs 
2000 [28] 
Medicaid ‘87 –‘96 2,476 2 years 
All health 
care 
cont. treat. vs treat. gap>44d $697k,l -$173l -$111l 
1996 USD 100% 
cont. treat. vs no treat. $4,711k,l -$283l $5,306l 
Pai 2010# 
[29] 
Medicaid ‘94 –‘03 nr nr nr 
Persistent vs intermittent  nr nr -$1,791*** 
nr USD 100% 
Persistent vs quitters nr nr -$1,484*** 
Persistent vs partial 
augmenters 
nr nr $1,935*** 
Persistent vs full augmenters nr nr $3,185*** 
Ahn 2008 
[30] 
Medicaid ‘94 –‘03 36,195 1 year 
All health 
care 
adherent vs switchers $701***k $1,086*** $3,654*** 
nr USD 100% 
Adherent vs non-adherent $559***k -$1,678*** -$408*** 
Database analysis  - Overfillers analysed separately 
Gilmer 
2004 [31] 
Medicaid ‘98 –‘00 1,619 1-3 year 
All health 
care 
MPR <0.5 vs 0.8-1.1 $2,388*** -$2,921*** -$1,337*** 
nr USD 100% MPR 0.5-0.79 vs 0.8-1.1 $1,664*** -$1,321*** -$102 (ns) 
MPR>1.1 vs 0.8-1.1 $1,447*** $1,172*** $4,539*** 
Eaddy 
2005 [32] 
Medicaid ‘99 –‘01 7,864 1 year 
Disease 
specific 
CMA<0.8 vs 0.8-1.25 
$1,788***
m 
-$912m (ns) $708m (ns) 
2001/ 
2002 USD 
nrn 
CMA>1.25 vs 0.8-1.25 
$7,260m 
(ns) 
$732m (ns) $8616m (ns) 
Dilokthorn-
sakul 2016 
[43] 
Hospital 
database 
Thailand 
’11-‘13 582 2 yearso 
All care billed 
by hospital 
MPR<0.8 vs 0.8-1.2 nr nr $143p (ns) 
2013 USD 100% 
MPR>1.2 vs 0.8-1.2 nr nr $116p (ns) 
Database analysis  - use of quasi-experimental design or analysis to control for unobserved confounding 
Zeber 2007 
[39] 
VA ‘00 –‘03 80,637 
40 
months 
All drugs and 
psych. hosp. 
Effect of higher drug copay: 
exempt vs non-exempt 
nr -$133***q nr 1999 USD 100% 
Farley 
2010 [33] 
Medicaid ’01-‘03 16,582 2 yearsr 
Mental 
health care 
PDC and treatment gap>90d nr -$46***s -$21* nr USD 100% 
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Jiang 2015 
[34] 
Medicaid 
+ private 
‘07 –‘13 32,374 2nd year 
All health 
care 
PDC>=0.8; PDC<0.8 
$27,664 
*** 
-$8,194*** $19,497* 
2013 USD 40%t 
Time to drug gap >15d of 
>360d; <360 
$34,178 
*** 
-$10,278 
*** 
$23,927* 
Other database analyses 
Marcus 
2008 [35] 
Medicaid ‘01 –‘03 35,815 variable 
Disease 
specific 
Any drug treatment 15 days 
before hospitalization (Y/N) 
nr nr nr 2005 USD 100% 
Markowitz 
2013 [36] 
Medicaid ‘04 –‘08 2,541 
18 
months 
All health 
care 
PDC>=0.8; PDC<0.8 nr nr nr 2010 USD 100% 
Cohort studies 
Knapp 
2004 [45] 
survey ’93-‘94 658 1 year 
All health & 
day careu 
Self-report 
£2,500 
(ns) 
nr £5,000 (ns) 2001 GBP 68% 
Salize 2009 
[46] 
MECCA 
RCT 
’02-‘05 507 1 year 
Mental 
health care 
‘drug compliance’ data 
collected 
nr 
8% (ns), 
40%*v  
-6% (ns), 
-18%*w 
2004 PPP 
Euros 
84% 
Novick 
2010 [49]; 
Hong 2010 
[47] 
SOHO 
study 
’00-‘04 5,364 3 years 
Disease 
specific 
Physician interview:  full 
adhere. vs partial adhere.  
nr nr £202 
nr GBP 100% 
Physician interview:  full 
adhere. vs  non adhere. 
£1024 nr £952 
King 2010 
[50]; King 
2014 [48] 
QUATRO 
RCT 
’02-‘03 409 1 year All costsx 
Morisky scale: 
0-2 vs 3-4 
nr nr -€6,380y (ns) 
2003 PPP 
Euros 
100% 
adhere. – adherence; admin. – administrative; AMQ – attitude to medication questionnaire; augment. – augmentation of treatment; CMA – Continuous 
medications available; CMR Continuous multiple interval Medication Availability; d – days; discont. – discontinuation; DAI – drug attitude inventory; GBP – 
British Pound; hosp. – hospitalization; KRW – South Korean Won; mod. – moderate; MPR – Medication Possession Ratio; nr – not reported; ns – not 
statistically significant; observ. – observation; PDC – Proportion of days covered; PPP – Purchasing Power Parity; psych. – psychiatric; QUATRO – The Quality 
of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers study; quart. – quartile; RCT - Randomised Controlled Trial; SES – 
Service Engagement Scale; sev. – severe; SOHO – Schizophrenia Outpatient Health Outcomes; treat. – treatment; USD - United States Dollar; VA – Veterans 
Health Administration; X survey – cross-sectional survey.  #Annualised mean costs for patients in category identified minus annualised mean costs for 
patients in category including full adherence (as opposed to excess fillers where identified). Data for schizophrenia patients reported where available. # 
Conference Abstract. * p<0.05. ** p<0.01. *** p<0.001. aIncluding schizo-affective disorder. bData not consistently reported in paper. cCost data reported 
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for subgroup of patients with schizophrenia. dCosts of arrests and involuntary assessments included. eData reported is weighted mean across patients 
prescribed typical, atypical and both antipsychotics. fMeans calculated after averaging data across adherence categories for cardio-metabolic drugs. gCost 
differences reported with respect to lowest adherence category (PDC<0.7). hPrice year not explicitly reported. iContinuous care defined as a year with 
outpatient psychiatric care and/or at least 180 days of antipsychotic medication. jCosts appear to be summed over period 2009-2011 without adjustment 
for inflation. kPsychiatric hospitalisation costs. lCosts derived after combining reported regression coefficients assuming the base category to be no 
treatment and that the ‘received drug treatment’ category including patients with and without treatment gaps. mReported cost differences are unadjusted; 
significance determined from regression analysis adjusting for baseline differences. nPopulation includes all patients prescribed antipsychotics. oAdherence 
assessed in first year, costs in second year. pReported costs are ‘only direct medical cost incurred in the hospital’ – it is not clear if the costs include drug 
treatment. qCalculated as the difference in difference between pharmacy costs reported in Table 2 of the paper for the exempt and the copayment eligible 
group for the periods before and after the change in copayment; significance determined from regression analysis of the natural logarithm of pharmacy 
costs. r12 month pre-test, 12 month post-test design. sNon-psychiatric medications. tProportion includes some patients diagnosed with both schizophrenia 
and bipolar disorder. uCosts included health care, social care, day care and sheltered employment. v8% increase in psychotropic drug costs (gamma model) 
and 40% increase in costs (log-normal model) associated with a change in compliance from good to average or from average to poor at baseline. w6% 
decrease in total costs (log-normal model) and 18% decrease in costs (gamma model) with a change in compliance from good to average or from average to 
poor at baseline. xSocietal perspective included health care, social care, criminal justice, informal care and productivity costs. yReduction in costs for a 
change from adherent to non-adherent for a white European man, aged 45, without tertiary education and resident in London.  
Table 1. Analyses of administrative data 
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Reference Interv-
ention 
No. of 
pati-
ents 
Follow-
up 
period  
Measure of 
adherence 
Impact of 
intervention on 
compliance 
Annualised difference in 
costs between intervention 
and control arms (statistical 
significance)# 
Price 
Year 
Patients 
with 
schizo-
phrenia 
hospital Drugs total 
Healey 1998 [51]; 
Kemp 1998 [52] 
Compliance 
therapy 
47 
18 
months 
Interview – seven 
point scale 
Significant 
increase in 
intervention arm 
nr nr 
-£939a 
(ns) 
1995/6 
GBP 
nr 
Stant 2007 [53]; 
Wunderlink 2007 
[54] 
Guided 
discontinuat
ion of APs 
128 
18 
months 
Randomised to 
discontinuation 
discontinuation: 
treatment, 54%;  
control, 8%  
-€3,425b 
(ns) 
-€394b 
(ns) 
-€4,769b 
(ns) 
2004 
Euros 
45% 
Gilden 2011 [55]; 
Staring 2010 [56] 
Adherence 
therapy 
109 1 year 
Compliance subscale 
of SES and interview 
Significant 
increase in 
intervention arm 
-€2,300c 
(ns) 
nr 
€514d 
(ns) 
2008 
Euros 
100% 
Henderson 2015 
[57]; Priebe 2016 
[58] 
Financial 
incentive 
141 1 year 
Proportion of depot 
prescriptions 
received 
Increase in 
intervention arm 
11.5% (p = 0.003) 
-£1,698e 
(ns) 
£177f 
(ns) 
£699g 
(ns) 
2010/11 
GBP 
92% 
#treatment effect of intervention; APs – Antipsychotic medication; GBP – British Pounds; nr – not reported; ns – not statistically significant; SES – Service 
Engagement Scale; aCalculated from weekly unadjusted difference between Intervention and control over 18 months. bCalculated from unadjusted 
difference between Intervention and control over 18 months following initiation of discontinuation in the treatment group. cPsychiatric and non-psychiatric 
hospital costs. dIntervention costs include Adherence therapy costs of €726 per patient. eMental health related hopsitalization costs. fSum of difference in 
costs for oral medications (data available for 133 patients) and depot medications (data available for 131 patients). gIntervention costs include financial 
incentives of £303 per patient. 
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Figure 1. Search results and literature selection 
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Figure 2. Assessment of quality of included studies 
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